Clinical Trials
61 trialsCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
RECOGNISE
University of Turin, Italy
CZCNRHNSCC
Sun Yat-sen University
MITO CERV 2
National Cancer Institute, Naples
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
V-CHANCE
National Cancer Institute, Naples
COSTIC
Sun Yat-sen University
Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
First Affiliated Hospital of Zhejiang University
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment
Shanghai Henlius Biotech
CETIDYL
Hôpital Franco-Britannique-Fondation Cognacq-Jay
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Shanghai Zhongshan Hospital
Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
Liaoning Cancer Hospital & Institute
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd.
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases
Yonsei University
A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer
Jiangsu Cancer Institute & Hospital
Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)
Shanghai Changzheng Hospital
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Fudan University
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
Fudan University
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis
Korea Cancer Center Hospital
CELIM2
Technische Universität Dresden
CARACAS
Gruppo Oncologico del Nord-Ovest
LERFOX-C
Karolinska University Hospital
I-Tackle
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer
Peking University
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
CRICKET
Gruppo Oncologico del Nord-Ovest
Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
Peking University
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
Huazhong University of Science and Technology
Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer
Shanghai Zhongshan Hospital
DEEPER
Japan Clinical Cancer Research Organization
A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab
National University Hospital, Singapore
OPTILIV
Association pour la Recherche sur le Temps Biologique et la Chronothérapie
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
CETMET
Karolinska University Hospital
Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer
Fudan University
XERT
Institute of Oncology Ljubljana
Treatment Selection According to Skin Reaction to Cetuximab
Institute of Oncology Ljubljana
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
Enzon Pharmaceuticals, Inc.
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
CLIME
Fudan University
Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma
University of Virginia
Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck
Theagenio Cancer Hospital